Celiac.com 12/04/2019 - There still is no easy and accurate way to monitor and diagnose celiac disease in patients who've been on a gluten-free diet for a while. Celiac disease patients on a gluten-free diet experience reactions to gluten, but researchers really don't understanding those reactions in any meaningful way. Systemic cytokine release was recently linked to reactivation of gluten immunity in celiac disease.
A team of researchers recently set out to define the nature and time-course of symptoms and interleukin-2 changes specific for celiac disease patients. Their study shows that interleukin-2 assessment could help doctors monitor and diagnose celiac disease in patients already following a gluten-free diet.
The research team included Jason A. Tye-Din, A. James M...

Celiac.com 05/18/2021 - Microbial transglutaminase, also known as ‘meat glue,’ is an enzyme commonly used in the meat industry to “glue” together smaller pieces of fish or meat to make a single larger piece from numerous smaller chunks. Microbial transglutaminase is usually unlabeled and largely invisible to consumers. 
We've done a few articles on this over the years, including What is Meat Glue, and Why is it Unsafe for People with Celiac Disease, and Meat Glue Ingredient Triggers Symptoms in Celiacs and Could Promote Disease.
According to meat glue manufacturers, microbial transglutaminase and its related products are safe, nonallergenic, nonimmunogenic, and nonpathogenic. Most regulatory authorities say it is “generally recognized as safe” for public users. However, moun...

Celiac.com 07/05/2021 - One of the many approaches to alternative treatments for celiac disease includes the inhibition of various bio-chemical or bio-mechanical factors that promote mucous damage in the guts of untreated celiacs. One focus has been on inhibiting small intestinal transglutaminase 2. In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which increases T cell stimulation and triggers mucosal damage. Inhibition of transglutaminase 2 is a potential treatment for celiac disease.
A team of researchers recently set out to determine whether ZED1227, a selective oral transglutaminase 2 inhibitor, can successfully inhibit transglutaminase 2, and reduce duodenal mucosal damage, as a potential treatment for celiac...

Celiac.com 01/06/2022 - Knowing which auto antigens are at play in any given autoimmune condition is a critical challenge for the understanding and diagnosis of autoimmune diseases. There are currently five known autoantigens in the nine-member transglutaminase protein family. 
Because transglutaminases commonly play a role in autoimmunity, a team of researchers recently set out to explore whether the remaining members might also act as autoantigens, but in presently unexplained disorders. 
The research team included Nils Landegren, Norito Ishii, Maribel Aranda-Guillén, Hörður Ingi Gunnarsson, Fabian Sardh, Åsa Hallgren, Mona Ståhle, Eva Hagforsen, Maria Bradley, Per-Henrik D. Edqvist, Fredrik Pontén, Outi Mäkitie, Liv Eidsmo, Lars Norlén, Adnane Achour, Ingrid Dahlbom, Ilma Kor...